Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance

Biochemical Pharmacology

Volumn 52, Issue 7, 1996, Pages 979-990

  Cummings, Jeffrey ^a   Macpherson, Janet S ^a   Meikle, Ian ^a   Smyth, John F ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

anthracenyl amino acids; antitumour activity; atypical MDR; chemosensitivity; multidrug resistance; topoisomerase I and II

Indexed keywords

AMINO ACID DERIVATIVE; ANTHRACENE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; GLYCOPROTEIN P; GYRASE INHIBITOR; MESSENGER RNA; NU ICRF 500; NU ICRF 505; NU ICRF 506; NU ICRF 513; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CHEMOSENSITIVITY; CHO CELL; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; HYPERSENSITIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030580063     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00301-2     Document Type: Article

References (71)

1. 1. Corbett AH and Osheroff N, When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 6: 586-597, 1993.
2. 2. Chen AY and Liu LF, DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191-218, 1994.
3. 3. Tewey KM, Rose ZC, Yang L, Halligan BD and Li LF, Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466-468, 1985.
4. 4. Hsiang Y-H, Hertzberg R, Hecht S and Liu LF, Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
5. 5. Davies SM, Robson CN, Davies SL and Hickson ID, Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 263: 17724-17729, 1988.
6. 6. Deffie AM, Batra JK and Goldenberg GJ, Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukaemia cell lines. Cancer Res 49: 58-62, 1989.
7. 7. Kasahara K, Fujiwara Y, Sugimoto Y, Nishi K, Tamura T, Matsuda T and Saijo N, Determinants of response to DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84: 113-118, 1992.
8. 8. Potmesil M, Hsiang Y-H, Liu LF, Bank B, Grossberg H, Kirshenbaum S, Forlenzar TJ, Penziner A, Kanganis D, Knowles D, Traganos F and Silber R, Resistance of human leukaemia and normal lymphocytes to drug induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48: 3537-3543, 1988.
9. 9. Lefevre D, Riou J-F, Ahomadegbe JC, Zhou D, Benard J and Riou G, Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and the acidic glutathione S-transferase. Biochem Pharmacol 41: 1967-1979, 1991.
10. 10. Volm M and Mattern J, Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients smoking habits. Carcinogenesis 13: 1947-1950, 1992.
11. 11. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K and Burke PJ, Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukaemia. Blood 83: 517-530, 1994.
12. 12. Bertrand R, Kerrigen D, Sarang M and Pommier Y, Cell death induced by topoisomerase inhibitors. Role of calcium in mammalian cells. Biochem Pharmacol 42: 77-85, 1991.
13. 13. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wylie AH, Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
14. 14. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y and Cossman J, bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53: 4251-4256, 1993.
15. 15. Liu LF, DNA topoisomerase poisons as antitumour drugs. Ann Rev Biochem 58: 351-375, 1989.
16. 16. Ratain MJ and Rowley JD, Therapy-related acute myeloid leukaemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Annal Oncol 3: 107-111, 1992.
17. 17. Negrini M, Felix CA, Martin C, Lange BJ, Nakamura T, Canaani E and Croce CM, Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;11) chromosome translocation in acute myeloid leukaemia. Cancer Res 53: 4489-4492, 1993.
18. 18. Gerwirtz DA, Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors. Biochem Pharmacol 42: 2253-2258, 1991.
19. 19. Cummings J and Smyth JF, DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 4: 533-543, 1993.
20. 20. Gromova II, Kjeldsen E, Svejstrup JQ, Alsner J, Christiansen K and Westergaard O, Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. Nucl Acids Res 21: 593-600, 1993.
21. 21. Feldhoff PW, Mirski SEL, Cole SPC and Sullivan DM, Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res 54: 756-762, 1994.
22. 22. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K and Andoh T, Inhibition of intracellular topoisomerase II by antitumour bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleanable complex-forming type inhibitors. Cancer Res 51: 4909-4916, 1991.
23. 23. Bae M-A, Tsuji T, Kondo K, Hirase T, Ishibashi M, Shigemori H and Kobayashi J, Inhibition of mammalian topoisomerase I by xestoquinone and halenaquinone. Biosci Biotech Biochem 57: 330-331, 1993.
24. 24. Li CJ, Averboukh L and Pardee AB, β-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem 268: 22463-22468, 1993.
25. 25. Tanabe K, Ikegami Y, Ishida R and Andoh T, Inhibition of topoisomerase II by antitumour agents bis(2,6-dioxopiperazines). Cancer Res 51: 4903-4908, 1991.
26. 26. Roca J, Ishida R, Berger JM, Andoh T and Wang JC, Antitumour bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci (USA) 91: 1781-1785, 1994.
27. 27. MacDonald TL, Lehnert EK, Loper JT, Chow KC and Ross WE, On the mechanism of interaction of topoisomerase II with chemotherapeutic agents. In: DNA topoisomerases in Cancer (Eds. Potmesil M and Kohn KW) pp. 199-215, Oxford University Press, New York, 1991.
28. 28. Morjani H, Riou J-F, Nabiev I, Lavelle F and Manfait M, Molecular and cellular interactions between intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy. Cancer Res 53: 4784-4790, 1993.
29. 29. Meikle I, Cummings J, Macpherson JS, Hadfield JD and Smyth JF, Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates. Biochem Pharmacol 49: 1747-1757, 1995.
30. 30. Robson CN, Hoban PR, Harris AL and Hickson ID, Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines. Cancer Res 47: 1560-1565, 1987.
31. 31. Hoban PR, Robson CN, Davies SM, Hall AG, Cattan AR, Hickson ID and Harris AL, Reduced topoisomerase II and elevated a class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C. Biochem Pharmacol 43: 685-693, 1992.
32. 32. Endicott JA, Juranka PF, Sarangi F, Gerlach JH, Deuchers KL and Ling V, Simultaneous expression of two P-glycoprotein genes in drug sensitive Chinese hamster ovary cells. Mol Cell Biol 7: 4075-4081, 1987.
33. 33. Ausubal FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K (Eds.), Current Protocols in Molecular Biology, Wiley Press, 1989.
34. 34. Jenkins JR, Ayton P, Jones T, Davies SL, Simmons SL, Harris AL, Sheer D and Hickson ID, Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucl Acids Res 20: 5587-5592, 1992.
35. 35. Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, Harris AL and Hickson ID, Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 72: 1454-1461, 1995.
36. 36. Glisson B, Gupta R, Smallwood-Kentro S and Ross WE, Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of acquired drug-stimulated DNA cleavage activity. Cancer Res 46: 1934-1938, 1986.
37. 37. Sullivan DM, Latham MD and Ross WE, Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res 47: 3973-3979, 1987.
38. 38. Constantinou A, Henning-Chubb C and Huberman E, Novobiocin-and phorbol-12-myristate-13-acetate-induced differentiation of human leukaemia cells associated with a reduction in topoisomerase II activity. Cancer Res 49: 1110-1117, 1989.
39. 39. Bradford M, A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
40. 40. Laemmli UK, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
41. 41. Towbin H, Staehelin T and Gordon J, Electrophoretic transfer of proteins from polyacrylamide to nitrocellulose sheet. Procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
42. 42. Plumb J, Milroy R and Kaye SB, Effects of the pH dependence of 3-(4,4-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity. Cancer Res 49: 4435-4440, 1989.
43. 43. van der Bliek AM, Baas F, van der Velde-Koerts T, Biedler JL, Meyers MB, Ozols RF, Hamilton TC, Joenje H and Borst P, Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res 48: 5927-5932, 1988.
44. 44. Gottesman MM and Pastan I, Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62: 385-427, 1993.
45. 45. Davies SM, Davies SL, Hall AG and Hickson ID, Isolation and partial characterization of a mammalian cell mutant hypersensitive to topoisomerase II inhibitors and X-rays. Mut Res 235: 111-118, 1990.
46. 46. Louie KG, Hamilton TC, Winker MA, Berhens BC, Tsuruo T, Klecker Jr RW, McKoy WM, Grotzinger KR, Myers CE, Young RC and Ozols RF, Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochem Pharmacol 35: 467-472, 1986.
47. 47. Rogan AM, Hamilton TC, Young RC, Klecker Jr RW and Ozols RF, Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1984.
48. 48. Beck WT, The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879-2887, 1987.
49. 49. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC and Liu LF, CPT overcomes mdr1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039-6044, 1991.
50. 50. Powis G, Free radical formation by antitumour agents. Free Radical Biol Med 6: 63-101, 1989.
51. 51. Graham MA, Newell DR, Butler J, Hoey B and Patterson LH, The effect of the anthrapyrazole antitumour agent C1941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Biochem Pharmacol 36: 3345-3351, 1987.
52. 52. Cummings J, Meikle I, Macpherson JS and Smyth JF, Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug sensitive and drug resistant human ovarian cancer cell lines determined by high-performance liquid chromatography. Cancer Chemother Pharmacol 37: 103-109, 1995.
53. 53. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M, DNA topoisomerase I - targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989.
54. 54. Langdon SP, Hendriks HR, Braakhuis B-J, Pratesi G, Berger DP, Fodstad O, Fiebig HH and Boven E, Preclinical phase II studies in human tumour xenografts: A European multicenter follow-up study. Annal Oncol 5: 415-422, 1994.
55. 55. Khelifa T, Casabianca-Pignede M-R, Rene B and Jacquemin-Sablon A, Expression of topoisomerase II α and β in Chinese hamster lung cells resistant to topoisomerase II inhibitors. Molec Pharmacol 46: 323-328, 1994.
56. 56. Matsumoto Y, Fujiwara T, Honjo Y, Sasoaka N, Tsuchida T and Nagao S, Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11. J Surg Oncol 53: 97-103, 1993.
57. 57. Baguley BC, Finlay GJ and Ching L-M, Resistance mechanisms to topoisomerase poisons: the application of cell culture methods. Oncol Res 4: 267-274, 1992.
58. 58. Schneider E, Horton JK, Yang C-H, Nakagawa M and Cowan KH, Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54: 152-158, 1994.
59. 59. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW and Hickson ID, Relationship between topoisomerase II levels and chemosensitivity in human tumour cell lines. Cancer Res 51: 6592-6595, 1991.
60. 60. Doyle LA, Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemother Pharmacol 34 (suppl) S32-S40, 1994.
61. 61. Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchers KL, Freedman MH and Goldenberg GJ, Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukaemia cell lines. Cancer Res 55: 78-82, 1995.
62. 62. Cummings J, Sumner AT, Slavotinek A, Meikle I, Macpherson JS and Smyth JF, Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500. Mut Res 344: 55-62, 1995.
63. 63. Watt PM and Hickson ID, Structure and function of type II DNA topoisomerase. Biochem J 303: 681-695, 1994.
64. 64. Boritzki RJ, Wolfard TS, Besserer JA, Jackson RC and Fry DW, Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 37: 4063-4068, 1988.
65. 65. Chen M and Beck WT, Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 53: 5946-5953, 1993.
66. 66. Gorbsky GJ, Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane: ADR-529] and ICRF-159 (Razoxane). Cancer Res 54: 1042-1048, 1994.
67. 67. Mattern MR, Hofman GA, Polsky RM, Funk LR, McCabe FL and Johnson RK, In vitro and in vivo effects of clinically important camptothecin analogues on multidrug resistant cells. Oncol Res 5: 467-474, 1993.
68. 68. Horiguchi T, Hayashi K, Tsubotani S, Linuma S, Harada S and Tanida S, New naphthacenecarboxamide antibiotics, TAN-1518 A and B, have inhibitory activity against mammalian DNA topoisomerase I. J Antibiotics 47: 545-556, 1994.
69. 69. de Jong S, Zijlstra JG, Mulder NH and de Vries EGE, Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol 28: 461-464, 1991.
70. 70. Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC and Andoh T, DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55: 2299-2303, 1995.
71. 71. Crow RT and Crothers DM, Inhibition of topoisomerase I by anthracycline antibiotics: evidence for general inhibition of topoisomerase I by DNA-binding agents. J Med Chem 37: 3191-3194, 1994.